New antibody treatment could tame rare brain disease Flare-Ups
NCT ID NCT07182409
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests whether monoclonal antibodies can safely and effectively treat acute attacks of neuromyelitis optica spectrum disorder (NMOSD), a rare disease that causes inflammation in the eyes and spinal cord. Researchers will enroll 40 adults experiencing a recent flare-up and measure changes in disability over six months. The goal is to find better ways to control these attacks and improve recovery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
monoclonal antibody
What this could lead to
If successful, this could point toward a more effective way to treat acute attacks of NMOSD, potentially reducing long-term disability.
What could go wrong
This is a small, early-stage study with only 40 participants, so results may not apply to everyone. The treatment may not work better than existing options or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NMOSD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••